From a poster on the other IH Cytodyn board: I
Post# of 148168
I WROTE TO NADER -
Someone on one of the message boards suggested that the lab analysis should include information on RANTES. If improvement on this metric is shown, I think the FDA would be more likely to designate leronlimab Emergency Use Authorization.
HE REPLIED -
Trust me, we don’t miss a bit (A THING) when it comes to these type of things.
With best regards
Nader